|

anti-BCMA CAR-T Clinical Trials

6 actively recruiting trials

Also known as: Bortezomib, Lenalidomide and Dexamethasone

Pipeline

Phase 2: 6

Top Sponsors

  • Institute of Hematology & Blood Diseases Hospital, China6

Indications

  • Cancer6
  • Multiple Myeloma4
  • Plasma Cell Leukemia2

Other6 trials

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
Phase 2
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
Phase 2
A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
Phase 2
BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
Phase 2
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
Phase 2
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.